Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124874 | 0.86 | NAMPT (0.38) | — | |
| SCHEMBL13936551 | 0.85 | HTR6 (0.36) | DRD2HTR6PNMT | |
| SCHEMBL22402472 | 0.79 | — | — | |
| SCHEMBL13976079 | 0.79 | ALOX15 (0.37) | ALOX15PNMT | |
| SCHEMBL22893348 | 0.78 | SOS1 (0.35) | DRD2 | |
| SCHEMBL13936550 | 0.78 | DRD2 (0.38) | DRD2DRD4 | |
| SCHEMBL13936552 | 0.77 | KCNA3 (0.33) | — | |
| SCHEMBL7880324 | 0.77 | CDK9 (0.36) | KDM4ELMNA | |
| SCHEMBL13538553 | 0.76 | TSHR (0.32) | — | |
| SCHEMBL7948775 | 0.75 | SIGMAR1 (0.48) | KDM4ELMNADRD2DRD4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11547709-B2 | Methods of treating disorders associated with castor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| WO-2022133034-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2020198526-A2 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| CN-105829308-B | Isochromene derivatives as phosphoinositide 3-kinase inhibitors | 奇斯药制品公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-01-25 | — | — | US | disclosed |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-09-21 | — | — | US | disclosed |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-08-04 | — | — | US | disclosed |
| US-9321786-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8633205-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| US-7994167-B2 | Pentafluorosulphanyl-substituted compound and its use for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547709-B2 | Methods of treating disorders associated with castor | HMGCR, GCDH, CYP11A1 | KDM4E 1116/4885LMNA 1621/4885ALOX15 978/4885 |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885LMNA 2409/4885ALOX15 979/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885LMNA 2409/4885ALOX15 979/4885 |
| US-20070004762-A9 | Pyrrolopyrimidines useful as inhibitors of protein kinase | PRKDC, MAP3K20, MAP3K5 | KDM4E 1549/4885LMNA 3416/4885ALOX15 4159/4885 |
| US-20170267685-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | KDM4E 2472/4885LMNA 3640/4885ALOX15 4281/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885LMNA 2409/4885ALOX15 979/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | KDM4E 1116/4885LMNA 1621/4885ALOX15 978/4885 |
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | PRKDC, DCK, CDK2 | KDM4E 1255/4885LMNA 3446/4885ALOX15 3878/4885 |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | HTR1A, HTR1B, HTR1D | KDM4E 4587/4885LMNA 3407/4885ALOX15 1170/4885 |
| US-20160221966-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885LMNA 2409/4885ALOX15 979/4885 |
| US-20180022713-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | KDM4E 3792/4885LMNA 2409/4885ALOX15 979/4885 |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | KDM4E 2472/4885LMNA 3640/4885ALOX15 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.